EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Research Progress and Clinical Challenges of Precision Targeted Therapy for Autoimmune Diseases

Mengyang He

Exploring Science Academic Conference Series · 11.08.2026 · 18 · 300-306

DOI: 10.70267/shbe.2026300306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploring Science Academic Conference Series, online erschienen am 11.08.2026. Verfasst von Mengyang He. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of autoimmune diseases is undergoing a paradigm shift from “broad -spectrum immunosuppression” toward “precision targeted intervention.” Although conventional synthetic disease - modifying antirheumatic drugs (such as methotrexate) remain the cornerstone of therapy, their efficacy ceiling and cumulative toxicity limit long-term use, and clinical practice still has safety gaps, such as inadequate folic acid supplementation. The advent of targeted biologic agents (e.g., TNF -α inhibitors, IL-6R antagonists) and JAK inhibitors has enabled precise blockade of specific inflammatory pathways. However, studies such as ORAL Surveillance have revealed a “safety paradox” of JAK inhibitors regarding cardiovascular and thrombotic risks, highlighting the need for a careful balance between efficacy and risk in clinical practice. To address the clinical challenge of secondary loss of response, precision -switching strategies grounded in immunogenicity theory and therapeutic drug monitoring —including same-target cycling and cross -pathway switching—have emerged as core approaches to optimize efficacy. Meanwhile, bispecific antibodies and CAR-T cell therapies have demonstrated potential breakthrough value in refractory autoimmune diseases; however, their long -term safety, suitability for specific patient populations, and accessibility require further validation through larger-scale clinical studies.

Zitieren

APA

He, M. (2026). Research Progress and Clinical Challenges of Precision Targeted Therapy for Autoimmune Diseases. Exploring Science Academic Conference Series, 18, 300-306. https://doi.org/10.70267/shbe.2026300306

Vancouver

He M. Research Progress and Clinical Challenges of Precision Targeted Therapy for Autoimmune Diseases. Exploring Science Academic Conference Series. 2026;18:300-306. doi:10.70267/shbe.2026300306

BibTeX
@article{He2026,
  author = {He, Mengyang},
  title = {Research Progress and Clinical Challenges of Precision Targeted Therapy for Autoimmune Diseases},
  journal = {Exploring Science Academic Conference Series},
  year = {2026},
  volume = {18},
  pages = {300--306},
  doi = {10.70267/shbe.2026300306}
}
Kostenlos starten →